Drug Profile
PRS 050
Alternative Names: Angiocal; PRS-050; PRS-050-PEG40Latest Information Update: 13 Jan 2015
Price :
$50
*
At a glance
- Originator Pieris
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 Jan 2015 Discontinued - Phase-I for Solid tumours (Recurrent, Refractory metastatic disease) in Germany (IV)
- 04 Dec 2012 PRS-050 is still in phase I trials for Solid tumours in Germany
- 13 Nov 2011 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) (3064172; 9131166)